Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Gains from Sales and Divestitures (2016 - 2026)

Seres Therapeutics (MCRB) has disclosed Gains from Sales and Divestitures for 11 consecutive years, with $124855.0 as the latest value for Q4 2025.

  • Quarterly Gains from Sales and Divestitures fell 94.31% to $124855.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $124855.0 through Dec 2025, down 94.31% year-over-year, with the annual reading at $124855.0 for FY2025, 94.31% down from the prior year.
  • Gains from Sales and Divestitures hit $124855.0 in Q4 2025 for Seres Therapeutics, up from $52160.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $2.2 million in Q4 2024 to a low of $650.0 in Q1 2021.
  • Historically, Gains from Sales and Divestitures has averaged $482774.1 across 5 years, with a median of $270712.0 in 2022.
  • Biggest five-year swings in Gains from Sales and Divestitures: crashed 99.48% in 2021 and later soared 439.89% in 2023.
  • Year by year, Gains from Sales and Divestitures stood at $650.0 in 2021, then surged by 43346.31% to $282401.0 in 2022, then skyrocketed by 439.89% to $1.5 million in 2023, then surged by 44.01% to $2.2 million in 2024, then plummeted by 94.31% to $124855.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for MCRB at $124855.0 in Q4 2025, $52160.0 in Q3 2025, and $35161.0 in Q2 2025.